Tandem’s Mobi pump wins FDA clearance for 7-day tubeless wearable set

Tandem Diabetes Care (Nasdaq: TNDM) has secured an FDA clearance for a tubeless version of its miniaturized automated insulin delivery system.

The Tandem Mobi’s new cartridge and infusion set converts the pump into a device that can be worn on the skin for up to a week, beating Insulet Omnipod 5’s wear time of 3 days.

Its full U.S. commercial launch is scheduled for the first half of next year, exclusively through pharmacy channels. Current in-warranty Mobi users will not need a new pump, just the compatible accessories — according to the company, Mobi was designed from the start to work with different wear options.

Sign up for Blog Updates